PBAC's latest decision on Rivastigmine: Recommended (2015). Considered for Treatment of mild to moderately severe Alzheimer-type dementia. This submission seeks listing of an additional patch strength (13.3 mg/24 hours) to provide an additional dosing option for patients with this condition.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Patients with mild to moderately severe Alzheimer-type dementia with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 10 or more, confirmed by or in consultation with a specialist/consultant physician.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Pivotal trial size
567 patients
Key trials
OPTIMA
Economic model
Not modelled
ICER note
Minor submission; no economic comparison presented